+ antigens expression in 21 h of experiments without mitogenic stimulation. Furthermore, this study revealed negative significant relationships of IFN-g secretion with regard to CD4
Introduction
The role of immune cells in the course of neoplastic disease, including cancers of the head and neck region, is not completely clear. Despite the lack of direct evidence that cells of the immune system can protect against the development and progression of cancer, clinical observations and experimental studies suggest their activity in the response against tumor cells of different origins. Unfortunately, little is known about the pathomechanisms and mutual interactions between tumor cells and the autologous immune cells i.e. the impact of neoplastic cells in modulating the function of cells involved in the immunological processes, the activity of T CD4 + and CD8 + lymphocytes and the regulation and determination of antitumor cellular immune response in patients with head and neck squamous cell carcinomas (HNSCC), in particular with carcinoma of the larynx. Detailed knowledge about the regulatory mechanisms influencing the final result of the immune response to tumor antigens, understanding of the interactions of cells involved in immunological processes ´ cancer cells, as well as indications of the immunological parameters associated with the clinical and morphological features of neoplastic infiltration, may therefore be important in determining the invasiveness of tumor lesions, and thus in assessing the clinical course, choice of optimal treatment and prognosis in patients with HNSCC. Precise knowledge of the immune status of a patient with cancer may also be one of the prognostic factors taken into consideration in selecting an appropriate model of postoperative care i.e. an indication of the extent of follow-up carried out in terms of postoperative early detection of cancer recurrence.
During the activation of T cells at their surface, the activation marker CD (cluster of differentiation) appears. Depending on the duration of activation response after the stimulus, CD markers can be divided into early stimulation (CD69 + and CD71 + ) and late activation (CD25 + , CD26 + , HLA/ /DR + ) antigens [1] . CD69 + antigen (also called induced activator molecule, AIM, MLR3) occurs mainly in stimulated T cells, but also on B lymphocytes and macrophages. CD69 + marker has the characteristics of pectin and it is involved in activating signal transduction, leading to the synthesis of various cytokines, including IL-2 and IFN-g and the receptor for IL-2 (IL-2R) [1, 2] . CD69 + is the earliest marker that is expressed on stimulated immune cells 2-4 hours after TCR/CD3 receptor stimulation [1, 2] . CD71 + antigen, which occurs in proliferating cells and macrophages, is also the receptor for transferrin and the iron transporting protein. It covalently links the chain of the TCR receptor on T cells and plays a role in signal transduction pathways. CD25 + antigen is one of three receptors for IL-2 (IL-2R), known as receptor a, occurring in activated T and B lymphocytes and monocytes [1] . Mitogenic or antigen stimulation of T cell causes the appearance of CD25 + on the surface of immunocompetent cells [3] . CD26 + (dipeptidyl peptidase IV) is a surface protein that exhibits the characteristics of a protease. It occurs constitutively in various cell types involved in immunological processes i.e. T cells, B, and monocytes. CD26 + appears about 48 hours after activation on T cells. The function of this molecule is to enhance lymphocyte activation. It stimulates the activation of T cells depending on CD3 and CD2 antigens, tyrosine phosphorylation of proteins involved in signal transduction after stimulation of TCR/CD3 receptor. CD26
+ marker substrates are proline-containing peptides such as growth factors, chemokines, neuropeptides, and vasoactive peptides. It also acts in the phenomenon of apoptosis, playing an important role in tumor development [4, 5] . HLA/DR + antigen is expressed on B cells, macrophages and it occurs during the later stages of T lymphocytes and NK cells activation. Increased expression of HLA/DR + appears about 24 hours after stimulation [1] . Non-cancerous/cancerous epithelium cells isolation. After radical laryngectomy, the surgical tissue specimens were excised aseptically immediately after operation from at least four tumor sites: two from the tumor centre and two from the tumor margin and two sites of normal noncancerous laryngeal epithelium (as far as possible away from the tumor) of the same tumor patients. Fragments of tissue were washed with PBS to remove contaminated blood and inserted in RPMI 1640 medium (Biomed, Poland) supplemented with antibiotics streptomycin/penicillin/gentamycin 1% v/v (Sigma, Aldrich, Germany). The whole procedure was performed on an ice plateau. Briefly, tissue specimens were cut with a surgical knife and minced with a scalpel. This was done in RPMI 1640 medium (Biomed, Poland) supplemented with antibiotics streptomycin/penicillin/gentamycin 2% v/v (Sigma, Aldrich, Germany). Fragments of tissues were then washed three times with Hanks solution (Biomed Lublin, Poland). Next, the tumor and normal epithelial pieces were digested overnight (for 18 h) in Nunc Petri-dishes with 0.16 mg/mL hyaluronidase (Sigma, Aldrich, Germany), 0.55 mg/mL collagenase (Sigma, Aldrich, Germany) and antibiotics streptomycin/penicillin/gentamycin 1% v/v (Sigma, Aldrich, Germany) at 37°C, 5% CO 2 (Cellstar Incubator). The digested tissues were pressed gently through a 50-μm (mesh) sieve (Sigma, Aldrich, Germany) with RPMI 1640 medium (Biomed, Poland). Subsequently, the suspension was washed three times with PBS (without Mg and Ca 2+ ) for 20 min at 8°C by centrifugation in a MPW--350R centrifuge at 1,800 rpm/500 rcf and poured over by dyspase solution 2.4 U/mL, incubated for 30 min at 37°C and resuspended in 1 mL PBS. The concentration of cells was estimated using a microscope and Bürker's chamber. To get rid of the apoptotic and necrotic cells, the columns of a Magnetic Cell Sorting Separator MACS (Miltenyi Biotec, Germany) and a Dead Cell Removal Kit was used. Cells were resuspended at a concentration of 1 × 10 5 cells/mL in RPMI 1640 medium. The isolated cells i.e. tumor marginal cells (TMC) and non-cancerous normal epithelial cells (NCC), were collected immediately after the procedure.
FACS analysis of early and late activation antigens on T CD4
+ and CD8 + lymphocytes. Our investigations were performed with the approval of the Ethical Committee of the Medical University of Lodz, Poland and the National Science Council, Poland (No RNN/15/03/KN). Blood was collected directly before premedication into pyrogen free Heparin Li-tubes (final concentration 10 U/mL) and resuspended at a concentration of 1 × 10 6 cells/mL in RPMI 1640 medium (Biomed, Poland) supplemented with antibiotics streptomycin/penicillin/gentamycin 1% v/v (Sigma, Aldrich, Germany). Next, blood was incubated in 24-well flat-bottomed plates (Nunc Corp., Roskilde, Denmark) in a final volume of 0.2 mL (per well) and collected after 24 h at 37°C, 5% CO 2 (Cellstar Incubator). The experiences with the use of mitogenic stimulation with 5 μg of PHA (phytohemagglutinin) in cultures were also performed. For immunostaining, the following conjugated antibodies were used: anti-CD4 FITC labeled (clone RPA-T4), anti-CD4 PE (SK3), anti-CD8 PE (RPA-T8), anti-CD69 APC (L78), anti-CD71 APC (M-A712), anti-CD25 PE (2A3), anti-CD26 PE (L272) and anti-HLA-DR APC (L243), all provided by BD Pharmingen. 100 ml of blood was mixed and incubated for 30 min. at room temperature with appropriate quantities of antibodies or isotype controls. Erythrocyte contamination was eliminated by the addition of lysing solution (BD Bioscience) into the samples. After a short incubation and rinsing, the samples were fixed with 1% paraformaldehyde and analyzed by flow cytometry (FACSCalibur TM, CELLQuestTM software; BD Bioscience). The cell analysis and gates were restricted to lymphocytes in dot-plot. The results were expressed as mean fluorescence intensity (MFI) of the labeled surface antigens or percent positive CD4 + or CD8 + cells.
ELISA for IL-10 and IFN-g g g g g measurement. Blood was collected directly before premedication (blood samples were collected before tumor samples) into pyrogen free Heparin Li-tubes (final concentration 10 U/mL). Peripheral blood mononuclear cells were checked and counted for viability using the trypan blue staining method. Next, whole blood was resuspended at a concentration of 1 × 10 6 cells/mL in RPMI 1640 medium and incubated in a 96-well plate in a final volume of 0.1 mL (per well). The supernatants of cultures were collected after 21 h and 72 h at 37°C, 5% CO 2 (Cellstar Incubator). Concentration of IL-10 and IFN-g was assayed using the immunoenzymatic method ELISA using Human IL-10 (sensitivity 2 pg/mL) and IFN-g (1 pg/mL) ELISA SET BD Opt EIA (San Diego, CA, USA). The samples' absorbance was read on an ELx808 reader at the wavelength 450 nm (BioTek Instruments, Winooski, VT, USA). The experiences with the use of mitogenic stimulation with 5 μg of PHA (phytohemagglutinin) in cultures were also performed. Statistical analysis of data. None of the parameters recorded in material studied passed tests for being normally distributed (Kolmogorov-Smirnov test), and they were analyzed with nonparametric analysis of variance by ranks (Kruskal--Wallis test, Spearman test) and within group differences by post hoc analysis with Mann-Whitney U test and Dunnett correction for multiple comparisons. A value of p £ 0.05 was considered statistically significant. All data was analyzed using STATISTICA version 9.0 (StatSoft, Poland).
Results
The activation antigens expression on T CD3 + CD4 Cytokine IL-10 and IFN-g g g g g secretion in the studied group and the control group
We assessed cytokine IL-10 and IFN-g secretion in whole peripheral blood at two time points (21 h and 72 h of incubation), in trials without and after mitogenic stimulation. The average concentrations of secreted cytokines in the studied group and the control group were compared. Our results indicated a significant difference of IFN-g level in 21 h culture with PHA (p = 0.02) between these two groups. The supernatants from patients with laryngeal carcinoma were characterized by a significantly lower level of IFN-g, compared to the group of volunteers. No other significant differences in experiments were noted. However, we noticed a trend towards IFN-g lower secretion in patients with laryngeal carcinoma, both in the trials without and with stimulation, as well as towards lower production of IL-10 after stimulation. The mean cytokine concentrations in the studied groups and the statistical test results are shown in Figures 3A and 3D .
To check whether the early activation antigens (CD69 Table 5 .
Discussion
In experimental studies in which the epithelial tumor cells of laryngeal carcinoma, as well as the normal epithelial cells of the larynx, were added to blood culture, a significant increase in the expression of early activation antigens i.e. CD4 + CD71 + and CD8 + CD71 + as well as the lack of significant differences for late stimulation markers on T cells, in addition to CD8 + CD25 + was confirmed. Confirmation of higher expression of the early activation antigens, and a significant reduction in the expression of the late activation markers on T cells in patients with squamous cell carcinoma of the larynx, compared to the group of volunteers, may indicate the cellular immune response fading and the occurrence of dysfunction in regulatory immune mechanisms in patients with cancer. The declining activity of T CD4 + and CD8 + cells and progressive dysfunction of regulatory mechanisms in laryngeal squamous cell carcinoma is also evidenced by no significant differences in the expression of the late activation markers in experimental studies in which the epithelial tumor cells of laryngeal cancer were added to blood culture. The results showed that in the initial phase of immune response associated with the appearance of tumor antigens, the activity of T lymphocytes, both CD4 + and CD8 + , is intense. The observed phenomenon may be related to the mobilization of immune mechanisms which are designed to prepare the cells involved in immunological processes for the appropriate antitumor response. It is linked, among others, with increased expression of MHC class I and MHC class II molecules, which remarkably enhance antigen presentation for T cells, activation of T lymphocytes that recognize an antigen, differentiation of T cells towards cytotoxic lymphocytes, and activation of CD8 + lymphocytes and www.fhc.viamedica.pl NK cells, which have the ability to direct inhibition of tumor cell proliferation and cytolytic activity against the tumor cells. It is also connected with induction of cytokines expression that stimulate the activity of Tc and Th1 lymphocytes, NK cells and interleukins which inhibit the functions of Th2 cells [3, [7] [8] [9] [10] [11] . The observed decrease in the percentage of T lymphocytes, both CD4 + and CD8 + , reduced expression of the late activation markers, and no significant differences in expression of activation antigens in most mixed cellular cultures, points to progressive disability and decrease in the effectiveness of antitumor immune mechanisms, increased with longer duration of tumor cell interactions. Nor can we ignore the role of the suppressive effects of tumor cells on the functions of immune cells. This can lead to the phenomenon of anergy and immunological tolerance in cancer patients, and it points to the importance of regulatory CD4 + lymphocytes, demonstrating an immunosuppressive effect on effector cells [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
Analysis of the relationships of the early and the late antigens expression on T CD4 + and CD8 + cells to the level of cytokines in peripheral blood also suggest complex disorders of regulatory mechanisms of the immune response. These observations are confirmed by the recorded negative correlations between the measured parameters, which indicate the absence of increased expression of the activation markers, despite the increased secretion of IFN-g in the analyzed cultures and the need to non-specifically stimulate the immunocompetent cells, conditioning the existence of the positive correlations between the parameters of the cellular immune response. No effect of IFN-g, which in normal conditions increases the expression of MHC molecules on the APC cells and enhances antigen presentation to lymphocytes Th, increases Tc lymphocytes cytotoxicity as well as induces expression of cytokines such as IL-1, IL-6, TNF, and thus stimulates the activity of T CD4 + and CD8 + cells, confirms the immunosuppressive role of tumor cells on T lymphocytes and indicates a defect in the immune response [3, [7] [8] [9] [10] [11] .
In the literature, it has been difficult to find publications in which the expression of activation antigens on cells involved in immunological processes in squamous cell carcinoma of the larynx have been analyzed in detail. The results of the analysis of the early and the late antigens activation in the study group and the control group, and the findings of experiments with cultures of isolated tumor cells, do not have their counterparts in the literature. This is new scientific information in the field of immunopathology of squamous cell carcinoma of the larynx, which cannot be directly compared to data obtained by other researchers. A few publications have evaluated the expression of activation markers on the immune system cells in the group of cancers of the head and neck region. Most of these, however, concerned the analysis of tumor infiltrating cells (TIL) and lymphocytes present in regional lymph nodes and cells of different origin such as monocytes and dendritic cells, less frequently cells in the bloodstream. This does not allow direct comparisons of results obtained in patients with laryngeal cancer [13, [22] [23] [24] [25] [26] [27] [28] [29] . In addition, the findings show large discrepancies in the assessment of the T cells activity in various types of head and neck cancers, and lead to a different conclusion regarding the expression of activation markers on T lymphocytes in patients with neoplastic disease [22] [23] [24] [25] [26] [27] [28] [29] . This indicates the necessity of an individual approach to the immunological phenomena observed in a particular type of cancer, in order to properly interpret the results. Only a few selected publications, whose authors have adopted a similar panel of activation markers on subpopulations of T lymphocytes and similar research methods, were used.
It should be emphasized that the results of the cited publications were related to heterogeneous groups of cancers of the head and neck region, which are characterized by a different biology. This must have affected the findings obtained by investigators and the final conclusions.
Despite these limitations, studies on the pathogenesis and immunopathology of head and neck carcinomas clearly indicate the existence of complex disorders in the regulatory mechanisms of immune cellular response as well as the suppression and decreased activity of T cells in cancer patients [22] [23] [24] [25] [26] [27] [28] [29] . One reason for the ineffectiveness of the mechanisms of immune cell response to tumor antigens may be the reduced rate and/or reduction in the number and activity of T CD4 + lymphocytes, also confirmed in this study, which has an impact on the function and activity of T CD8 + cells. CD4 + T cells play a key role in initiating and sustaining the immune responses directed against the tumor cells with T CD8 + lymphocytes. CD4 + T cells are important in preventing anergy of cytotoxic lymphocytes and are involved in the formation of memory CD8 + subpopulation, as well as stimulating macrophages and eosinophils present in the tumor stroma [30, 31] . In light of the role of T CD4 + lymphocytes in the activation of antitumor mechanisms, reducing the activity of this subpopulation of T cells results in decreased activity and abnormal cytotoxic T CD8 + cell function, but also of other cells involved in immunological processes such as CD56 + NK cells and macrophages, actively involved in the cellular response [22] [23] [24] [25] [26] [27] [28] [29] . Evidence of suppression of www.fhc.viamedica.pl the immune response and reduction in the cytotoxic activity of defense mechanisms directed against tumor antigens, is provided by the diminished expression of surface molecules (perforins, granzymes, FasL receptors) on CD8 + T cells and CD56 + NK cells confirmed in studies by other authors [22] . As mentioned earlier in this discussion, the phenomenon of apoptosis of T CD4
+ and CD8 + cells occurring in cancer patients, repopulation of lymphocytes from naïve cells as well as the immune response determined by the activity of memory cells are the resultant of immune mechanisms in cancer disease [8, 12, 23, 24, 28] . A detailed assessment of T CD4 + and CD8 + lymphocytes, including memory cells, naïve cells and Treg lymphocytes, was not analyzed in the studied group of squamous cell carcinoma of the larynx. However, in the context of the results and to further analyze the findings of experiments and clinical observations, it seems necessary to give a brief overview of the importance of shifts in T-cell subtypes, which impact the activity of the examined populations.
In the literature, researchers have emphasized the need for diversification of CD4 + subpopulation in CD4 , to obtain objective conclusions about the activity and the number of lymphocytes circulating in patients with cancer [25, 32] .
Kuss et al. [25] showed significant reductions in both studied subsets of CD4 + T lymphocytes, both CD4 CD4 + CD45RO -CD27 + and CD4 + CD45RO + in patients with cancers of the head and neck. The same authors, performing research in a different group of patients, have also shown significant reductions in the number of CD4 + T cells, while also highlighting the presence of characteristic shifts in the subtypes of these cells, i.e. a significant reduction in the number of CD4 + CD45RO -CD27 + and an increase in subpopulations of memory cells in the whole blood of patients with HNSCC [32] . Also important in determining the activity and the number of cells involved in immunological processes is differentiation of T CD8 
CD45RO
-CD28 + /CD8 + CD28 -. The observed phenomenon causes that in the pheripheral blood dominate the less mature and active cells, which are recruited from naïve T cells. In addition, severe apoptosis and decrease in the percentage of CD8 + CD28 -effector cells, which have the ability to cancer cells lysis and IFN-g production in response to the presence of tumor antigens and exhibit high expression of granzyme B, explain the tumor progression. The results presented in a few publications regarding the evaluation of the expression of activation markers on T CD4
+ and CD8 + cells in carcinomas of the head and neck region, show large discrepancies in assessing the activity of immune cells [22, 33, 34] . Differences in the conclusions reached may be associated with the aforementioned different methodologies, but also there have been insufficient studies in heterogeneous groups of head and neck cancers of different origin.
Bose et al. [22] analyzed the expression of CD69 + molecules on isolated peripheral blood T cells in patients with cancers of the head and neck region and confirmed the reduced activity of immune cells, assessed in a 96 hour experience, even after stimulation with phytohemagglutinin (PHA). Aarstad et al. [33] also assessed the presence of selected activation antigens on T cells circulating in patients with HNSCC and the relationship of markers with the effectiveness of anticancer immunological mechanisms. The researchers did not find significant differences in the expression of activation markers examined in the study group and control group. Vidal-Rubino et al. [34] , who evaluated the presence of CD69 + molecules on T cells in regional lymph nodes with histologically confirmed lymphonodulitis reactiva, also found no significant differences in the expression of CD69 + antigen on immunocompetent cells in patients with head and neck carcinomas, compared to the expression of this marker in normal structured lymph nodes in the control group.
In the literature, we found no publications featuring an analysis of the expression of HLA/DR + on circulating blood cells involved in immunological processes in HNSCC cancers. Most of the articles concerned the analysis of the activity of the marker on cancer cells isolated from tumor or cell lines and assessing correlation of coexpressed HLA/DR + on both tumor cells and immune cells, mainly on tumor infiltrating lymphocytes (TIL) [16, [35] [36] [37] [38] [39] . Evaluation of HLA/DR + on these cell types was not studied in this group of squamous cell carcinoma of the larynx, but the results presented in the literature clearly indicate the interactions and the effect of tumor cells on the ) and the ability to infiltrate the tumor front in squamous cell carcinoma of the larynx.
The presented results confirm the importance of not only MHC class I antigens, but also MHC class II molecules on tumor cells in the antigens presentation and activation of CD8 + T cells, as well as the CD4 + subpopulation, which also plays an important role in the antitumor response. This is demonstrated by the studies of genetic and structural changes that lead to disturbances in expression of MHC class I molecules and MHC class II antigens on tumor cells and indicate the relationship of these aberrations with a reduced activity of effector cells and the phenomenon of 'tumor escape' against the defense mechanisms of cellular immune response [35] [36] [37] [38] [42] [43] [44] [45] .
In assessing the activity of immune cells, the regulatory role of Treg cells with immunosuppressive properties is also important. Several investigators have confirmed the role of these cells in promoting tumor development and progression of head and neck region carcinomas [12-21, 26, 46] . It should be emphasized that the activity of immune cells is also a result of immunological mechanisms regulated by immunosuppressive regulatory Treg cells (CD4  + CD25   +high   Foxp   3+ ), which exhibit inhibitory properties in particular in relation to CD8 + and CD4 + . Regulation of immune response dependent on the suppressive Treg cells, which may be more than 30% of the subpopulation of CD4 + T cells, cannot remain without influence on the activity of T CD4 + CD25 -and CD8 + cells [12, 18, 46, 47] . In the literature, the results of research on Treg activity in various cancers of the head and neck region clearly show an increase in the percentage of these cells, from 15.2% to as much as 25-30% of CD4 + cells in patients with HNSCC, compared to the control group, for which a percentage of this subpopulation was 5-10% [12, 18, 46, 47] . Badoual et al. [48] analyzed the activity of T cells infiltrating the tumor stroma and the relationship between subpopulations of T lymphocytes in cancers of the head and neck region and showed a significant advantage of the number of activated T CD4 + CD25 +high in patients with cancers of the head and neck region underwent apoptosis to a much greater extent than CD4 + CD25 -, which showed a diminished ability to bind V annexin. Other authors also showed increased sensitivity of T regulatory cells to apoptosis, compared to CD4 + CD25 -lymphocytes. The researchers point to the phenomenon of preferential Treg movement to the tumor tissue as one of the escape mechanisms from programmed death. This implies that the circuit is dominated by less mature Treg cells, recruited from naïve CD4 + T cells (CD4 + CD45RO -CD27 + ) or from active, highly differentiated cells that have lost the ability to migrate, as well as their helper or cytotoxic properties [18, 47] . Most authors have confirmed, however, an increased number and increased activity of CD4 + CD25 +high Treg cells, both in the tumor infiltrating lymphocytes population TIL and circulating blood cells, which to the greatest extent determines the development, progression and higher degree of invasiveness of neoplastic infiltration in patients with tumors of various origins, including patients with head and neck carcinomas [12-17, 19-21, 45-47] . www.fhc.viamedica.pl
